ALNYLAM PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $87.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $87.73M, a 22.23% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $71.26M, a 23.20% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $109.34M, a 134.57% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $112.81M, a 25.21% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $352.75M, a 28.12% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $275.32M, a 21.89% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $225.87M, a 4.86% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $237.40M, a 41.06% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $87.73M 10-Q · filed 2026-07-30 | $158.99M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $71.26M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $352.75M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $109.34M 10-Q · filed 2025-10-30 | $222.15M derived: sum of 2 quarters · filed 2026-07-30 | $279.99M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $112.81M 10-Q · filed 2026-07-30 | $170.65M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $57.84M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $275.32M 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $46.61M 10-Q · filed 2025-10-30 | $136.71M derived: sum of 2 quarters · filed 2025-10-30 | $182.86M derived: sum of 3 quarters · filed 2025-10-30 | |
| 2024-06-30 | $90.10M 10-Q · filed 2025-10-30 | $136.25M derived: sum of 2 quarters · filed 2025-10-30 | ||
| 2024-03-31 | $46.16M 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $225.87M 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $64.87M 10-Q · filed 2024-10-31 | $141.86M derived: sum of 2 quarters · filed 2024-10-31 | $183.00M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $76.99M 10-Q · filed 2024-10-31 | $118.13M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $41.14M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $237.40M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $129.13M 10-Q · filed 2023-11-02 | $163.59M derived: sum of 2 quarters · filed 2023-11-02 | $193.64M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $34.45M 10-Q · filed 2023-11-02 | $64.50M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $30.05M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $168.30M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $33.70M 10-Q · filed 2022-10-27 | $66.62M derived: sum of 2 quarters · filed 2022-10-27 | $122.92M derived: sum of 3 quarters · filed 2022-10-27 | |
| 2021-06-30 | $32.93M 10-Q · filed 2022-10-27 | $89.22M derived: sum of 2 quarters · filed 2022-10-27 | ||
| 2021-03-31 | $56.30M 10-Q · filed 2022-10-27 | |||
| 2020-12-31 | $142.99M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $40.23M 10-Q · filed 2021-10-28 | $73.94M derived: sum of 2 quarters · filed 2021-10-28 | $108.51M derived: sum of 3 quarters · filed 2021-10-28 | |
| 2020-06-30 | $33.71M 10-Q · filed 2021-10-28 | $68.28M derived: sum of 2 quarters · filed 2021-10-28 | ||
| 2020-03-31 | $34.58M 10-Q · filed 2021-10-28 | |||
| 2019-12-31 | $177.23M 10-K · filed 2022-02-10 | |||
| 2019-09-30 | $46.66M 10-Q · filed 2020-11-05 | $77.46M derived: sum of 2 quarters · filed 2020-11-05 | $110.00M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $30.80M 10-Q · filed 2020-11-05 | $63.34M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $32.54M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $158.64M 10-K · filed 2021-02-11 | |||
| 2018-09-30 | $88.41M 10-Q · filed 2019-10-31 | $110.41M derived: sum of 2 quarters · filed 2019-10-31 | $129.87M derived: sum of 3 quarters · filed 2019-10-31 | |
| 2018-06-30 | $22.00M 10-Q · filed 2019-10-31 | $41.46M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $19.46M 10-Q · filed 2019-10-31 | |||
| 2017-12-31 | $91.32M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $74.18M 10-K · filed 2019-02-14 | |||
| 2015-12-31 | $45.78M 10-K · filed 2018-02-15 | |||
| 2014-12-31 | $33.06M 10-K · filed 2017-02-15 | |||
| 2013-12-31 | $20.70M 10-K · filed 2016-02-12 | |||
| 2012-12-31 | $12.36M 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $16.68M 10-K · filed 2014-02-20 | |||
| 2010-12-31 | $19.12M 10-K · filed 2013-02-19 | |||
| 2009-12-31 | $19.73M 10-K · filed 2011-02-18 | |||
| 2008-12-31 | $16.38M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |